International Stem Cell

International Stem Cell R&D per Employee

The R&D Spending per Employee of International Stem Cell (ISCO) as of Oct 11, 2026 is 20,727.27 USD. In the previous year, R&D Spending per Employee was 19,909.09 USD — a change of 4.11% (higher).

R&D per Employee

20,727.27USD

YoY

4.11%

Last updated:

R&D Spending per Employee of International Stem Cell is 2025 20,727.27 USD. R&D Spending per Employee of International Stem Cell was 2024 19,909.09 USD. It decreases by 4.11% higher compared to the previous year.

The International Stem Cell R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2018
72,606.06 USD
Jan 1, 2019
42,000.00 USD
Jan 1, 2020
29,939.39 USD
Jan 1, 2021
21,060.61 USD
Jan 1, 2022
14,909.09 USD
Jan 1, 2023
15,484.85 USD
Jan 1, 2024
19,909.09 USD
Jan 1, 2025
20,727.27 USD
The International Stem Cell R&D per Employee history
YEARR&D per EmployeeYoY
20,727.27USD+4.11%
19,909.09USD+28.57%
15,484.85USD+3.86%
14,909.09USD-29.21%
21,060.61USD-29.66%
29,939.39USD-28.72%
42,000.00USD-42.15%
72,606.06USD-9.86%
80,545.45USD-6.93%
86,545.45USD+5.50%
82,030.30USD-49.74%
163,212.12USD—
Access this data via the Eulerpool API

International Stem Cell Stock analysis

What does International Stem Cell do? International Stem Cell Corp (ISCO) is a biotechnology company founded in 2005 and headquartered in Carlsbad, California. It specializes in the development and manufacture of stem cell products for therapeutics and research purposes. ISCO specializes in the production of "human parthenogenetic stem cells" (hpSCs). This means that they produce stem cells from human egg cells that can replicate without fertilization by sperm. The company is a leader in this field and has filed over 80 patents worldwide. ISCO has various business areas, including life science research, therapeutics, dermatology, and animal health. The company partners with various industries, including academic institutions, pharmaceutical and biotechnology companies, and government agencies. One of their biggest partnerships is with the Chinese company Sino Biopharmaceuticals. ISCO offers a variety of products, including in vitro diagnostics for testing genetic diseases such as Huntington's and food allergies. However, the diagnostics division of the company is a small department primarily focused on research and development purposes. ISCO also has a dermatology division called Lifeline Skin Care, which manufactures skincare products based on human stem cells. These products have been developed for improving skin texture and reducing scars. Lifeline Skin Care is a luxury brand for skincare products currently sold in over 15 countries worldwide. In terms of animal health, ISCO recently launched a new division called Lifeline Animal Health. They are developing animal therapeutics based on hpSCs. The company has already developed the first animal therapeutic for dogs approved for the treatment of hip dysplasia. However, ISCO primarily focuses on the development of therapeutics for human stem cells. The company aims to be a global leader in the development of stem cell therapeutics. Their first product, CytoCor for heart disease, is already in clinical phase 1b/2a. The drug is intended to help reduce damage after a heart attack and improve heart function. ISCO also plans to develop therapeutics for other indications, including Alzheimer's disease, based on hpSCs. The company has a strong partnership with the California Institute for Regenerative Medicine, which focuses on stem cell research and their use in medicine. ISCO is a leading company in stem cell research and development. They have a unique approach to stem cell production and offer a variety of products and services for various industries. The company aims to develop groundbreaking stem cell therapeutics and change the way diseases are treated. International Stem Cell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about International Stem Cell stock

R&D Spending per Employee of International Stem Cell is 20,727.27 USD in 2025.

R&D Spending per Employee of International Stem Cell changed from 19,909.09 USD to 20,727.27 USD, representing a 4.11% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee International Stem Cell since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's International Stem Cell historically and in real time.

Access this data via the Eulerpool API

Workforce — International Stem Cell

All Key Metrics — International Stem Cell